{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:54:21Z","timestamp":1794354861384,"version":"4.9.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874172"],"award-info":[{"award-number":["81874172"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303137"],"award-info":[{"award-number":["82303137"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103019"],"award-info":[{"award-number":["82103019"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073030"],"award-info":[{"award-number":["82073030"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270825"],"award-info":[{"award-number":["82270825"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M710170"],"award-info":[{"award-number":["2022M710170"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ20083"],"award-info":[{"award-number":["2022JJ20083"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","award":["2022ZZTS0873"],"award-info":[{"award-number":["2022ZZTS0873"]}],"id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Abnormal expression of Cylindromatosis (CYLD), a tumor suppressor molecule, plays an important role in tumor development and treatment. In this work, we found that CYLD binds to class I histone deacetylases (HDAC1 and HDAC2) through its N-terminal domain and inhibits HDAC1 activity. RNA sequencing showed that CYLD-HDAC axis regulates cellular antioxidant response via Nrf2 and its target genes. Then we revealed a mechanism that class I HDACs mediate redox abnormalities in CYLD low-expressing tumors. HDACs are central players in the DNA damage signaling. We further confirmed that CYLD regulates radiation-induced DNA damage and repair response through inhibiting class I HDACs. Furthermore, CYLD mediates nasopharyngeal carcinoma cell radiosensitivity through class I HDACs. Thus, we identified the function of the CYLD-HDAC axis in radiotherapy and blocking HDACs by Chidamide can increase the sensitivity of cancer cells and tumors to radiation therapy both in vitro and in vivo. In addition, ChIP and luciferase reporter assays revealed that CYLD could be transcriptionally regulated by zinc finger protein 202 (ZNF202). Our findings offer novel insight into the function of CYLD in tumor and uncover important roles for CYLD-HDAC axis in radiosensitivity, which provide new molecular target and therapeutic strategy for tumor radiotherapy.<\/jats:p>","DOI":"10.1038\/s41419-024-06419-w","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T10:02:45Z","timestamp":1706522565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Yueshuo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longlong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Bode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6695-9906","authenticated-orcid":false,"given":"Qiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2118-1117","authenticated-orcid":false,"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-629X","authenticated-orcid":false,"given":"Jia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-3336","authenticated-orcid":false,"given":"Ya","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"6419_CR1","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/cdd.2017.46","volume":"24","author":"M Lork","year":"2017","unstructured":"Lork M, Verhelst K, Beyaert R. CYLD, A20 and OTULIN deubiquitinases in NF-kappaB signaling and cell death: so similar, yet so different. Cell Death Differ. 2017;24:1172\u201383. https:\/\/doi.org\/10.1038\/cdd.2017.46","journal-title":"Cell Death Differ"},{"key":"6419_CR2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.molcel.2007.12.018","volume":"29","author":"D Komander","year":"2008","unstructured":"Komander D, Lord CJ, Scheel H, Swift S, Hofmann K, Ashworth A, et al. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell. 2008;29:451\u201364. https:\/\/doi.org\/10.1016\/j.molcel.2007.12.018","journal-title":"Mol Cell"},{"key":"6419_CR3","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.str.2004.07.012","volume":"12","author":"K Saito","year":"2004","unstructured":"Saito K, Kigawa T, Koshiba S, Sato K, Matsuo Y, Sakamoto A, et al. The CAP-Gly domain of CYLD associates with the proline-rich sequence in NEMO\/IKKgamma. Structure. 2004;12:1719\u201328. https:\/\/doi.org\/10.1016\/j.str.2004.07.012","journal-title":"Structure"},{"key":"6419_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00153-8","volume":"5","author":"Y Li","year":"2021","unstructured":"Li Y, Shi F, Hu J, Xie L, Zhao L, Tang M, et al. Stabilization of p18 by deubiquitylase CYLD is pivotal for cell cycle progression and viral replication. NPJ Precis Oncol. 2021;5:14. https:\/\/doi.org\/10.1038\/s41698-021-00153-8","journal-title":"NPJ Precis Oncol"},{"key":"6419_CR5","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41379-018-0018-6","volume":"31","author":"M Rito","year":"2018","unstructured":"Rito M, Mitani Y, Bell D, Mariano FV, Almalki ST, Pytynia KB, et al. Frequent and differential mutations of the CYLD gene in basal cell salivary neoplasms: linkage to tumor development and progression. Mod Pathol. 2018;31:1064\u201372. https:\/\/doi.org\/10.1038\/s41379-018-0018-6","journal-title":"Mod Pathol"},{"key":"6419_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.molcel.2009.04.031","volume":"34","author":"JE Hutti","year":"2009","unstructured":"Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell. 2009;34:461\u201372. https:\/\/doi.org\/10.1016\/j.molcel.2009.04.031","journal-title":"Mol Cell"},{"key":"6419_CR7","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1002\/jcp.27220","volume":"234","author":"E Ghadami","year":"2019","unstructured":"Ghadami E, Nikbakhsh N, Fattahi S, Kosari-Monfared M, Ranaee M, Taheri H, et al. Epigenetic alterations of CYLD promoter modulate its expression in gastric adenocarcinoma: a footprint of infections. J Cell Physiol. 2019;234:4115\u201324. https:\/\/doi.org\/10.1002\/jcp.27220","journal-title":"J Cell Physiol"},{"key":"6419_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2217\/fon.10.187","volume":"7","author":"R Massoumi","year":"2011","unstructured":"Massoumi R. CYLD: a deubiquitination enzyme with multiple roles in cancer. Future Oncol. 2011;7:285\u201397. https:\/\/doi.org\/10.2217\/fon.10.187","journal-title":"Future Oncol"},{"key":"6419_CR9","doi-asserted-by":"publisher","unstructured":"Schulze, B Down-regulation of CYLD as a trigger for NF-\u03baB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Int J Oncol. 2010:38. https:\/\/doi.org\/10.3892\/ijo_00000831","DOI":"10.3892\/ijo_00000831"},{"key":"6419_CR10","doi-asserted-by":"publisher","unstructured":"Down-regulation of the tumor suppressor CYLD enhances the transformed phenotype of human breast cancer cells. Anticancer Res. 2017:37. https:\/\/doi.org\/10.21873\/anticanres.11717","DOI":"10.21873\/anticanres.11717"},{"key":"6419_CR11","doi-asserted-by":"publisher","unstructured":"Suenaga N, Kuramitsu M, Komure K, Kanemaru A, Takano K, Ozeki K, et al. Loss of tumor suppressor CYLD expression triggers cisplatin resistance in oral squamous cell carcinoma. Int J Mol Sci. 2019:20. https:\/\/doi.org\/10.3390\/ijms20205194","DOI":"10.3390\/ijms20205194"},{"key":"6419_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0800-4","volume":"12","author":"A Sharda","year":"2020","unstructured":"Sharda A, Rashid M, Shah SG, Sharma AK, Singh SR, Gera P, et al. Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells. Clin Epigenetics. 2020;12:4 https:\/\/doi.org\/10.1186\/s13148-019-0800-4","journal-title":"Clin Epigenetics"},{"key":"6419_CR13","doi-asserted-by":"publisher","unstructured":"Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016:6. https:\/\/doi.org\/10.1101\/cshperspect.a026831","DOI":"10.1101\/cshperspect.a026831"},{"key":"6419_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/s0140-6736(19)30956-0","volume":"394","author":"Y Chen","year":"2019","unstructured":"Chen Y, Chan A, Le Q, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64\u201380. https:\/\/doi.org\/10.1016\/s0140-6736(19)30956-0","journal-title":"Lancet"},{"key":"6419_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-020-00376-4","volume":"6","author":"Y Cao","year":"2021","unstructured":"Cao Y, Xie L, Shi F, Tang M, Li Y, Hu J, et al. Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study. Signal Transduct Target Ther. 2021;6:15. https:\/\/doi.org\/10.1038\/s41392-020-00376-4","journal-title":"Signal Transduct Target Ther"},{"key":"6419_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrclinonc.2015.120","volume":"12","author":"D Schaue","year":"2015","unstructured":"Schaue D, McBride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015;12:527\u201340. https:\/\/doi.org\/10.1038\/nrclinonc.2015.120","journal-title":"Nat Rev Clin Oncol"},{"key":"6419_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"6419_CR18","doi-asserted-by":"publisher","first-page":"11921","DOI":"10.7150\/thno.46006","volume":"10","author":"J Hu","year":"2020","unstructured":"Hu J, Li Y, Li H, Shi F, Xie L, Zhao L, et al. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy. Theranostics. 2020;10:11921\u201337. https:\/\/doi.org\/10.7150\/thno.46006","journal-title":"Theranostics"},{"key":"6419_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41392-021-00793-z","volume":"6","author":"C Da","year":"2021","unstructured":"Da C, Pu J, Liu Z, Wei J, Qu Y, Wu Y, et al. HACE1-mediated NRF2 activation causes enhanced malignant phenotypes and decreased radiosensitivity of glioma cells. Signal Transduct Target Ther. 2021;6:399. https:\/\/doi.org\/10.1038\/s41392-021-00793-z","journal-title":"Signal Transduct Target Ther"},{"key":"6419_CR20","doi-asserted-by":"publisher","first-page":"334ra351","DOI":"10.1126\/scitranslmed.aad6095","volume":"8","author":"H Wang","year":"2016","unstructured":"Wang H, Liu X, Long M, Huang Y, Zhang L, Zhang R, et al. NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Sci Transl Med. 2016;8:334ra351. https:\/\/doi.org\/10.1126\/scitranslmed.aad6095","journal-title":"Sci Transl Med"},{"key":"6419_CR21","doi-asserted-by":"publisher","first-page":"11067","DOI":"10.1093\/nar\/gkab871","volume":"49","author":"L Yang","year":"2021","unstructured":"Yang L, Shen C, Estrada-Bernal A, Robb R, Chatterjee M, Sebastian N, et al. Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair. Nucleic Acids Res. 2021;49:11067\u201382. https:\/\/doi.org\/10.1093\/nar\/gkab871","journal-title":"Nucleic Acids Res"},{"key":"6419_CR22","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/09553008914552491","volume":"56","author":"G Steel","year":"1989","unstructured":"Steel G, McMillan T, Peacock J. The 5Rs of radiobiology. Int J Radiat Biol. 1989;56:1045\u20138. https:\/\/doi.org\/10.1080\/09553008914552491","journal-title":"Int J Radiat Biol"},{"key":"6419_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"R Huang","year":"2020","unstructured":"Huang R, Zhou P. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020;5:60 https:\/\/doi.org\/10.1038\/s41392-020-0150-x","journal-title":"Signal Transduct Target Ther"},{"key":"6419_CR24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41575-019-0247-2","volume":"17","author":"A Buckley","year":"2020","unstructured":"Buckley A, Lynam-Lennon N, O\u2019Neill H, O\u2019Sullivan J. Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nat Rev Gastroenterol Hepatol. 2020;17:298\u2013313. https:\/\/doi.org\/10.1038\/s41575-019-0247-2","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"6419_CR25","doi-asserted-by":"publisher","first-page":"10639","DOI":"10.2147\/cmar.S268216","volume":"12","author":"Y Lin","year":"2020","unstructured":"Lin Y, Wang L, Luo W, Zhou X, Chen Y, Yang K, et al. CYLD promotes apoptosis of nasopharyngeal carcinoma cells by regulating NDRG1. Cancer Manag Res. 2020;12:10639\u201349. https:\/\/doi.org\/10.2147\/cmar.S268216","journal-title":"Cancer Manag Res"},{"key":"6419_CR26","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/cr.2014.136","volume":"24","author":"Y Yang","year":"2014","unstructured":"Yang Y, Ran J, Liu M, Li D, Li Y, Shi X, et al. CYLD mediates ciliogenesis in multiple organs by deubiquitinating Cep70 and inactivating HDAC6. Cell Res. 2014;24:1342\u201353. https:\/\/doi.org\/10.1038\/cr.2014.136","journal-title":"Cell Res"},{"key":"6419_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/emboj.2009.317","volume":"29","author":"SA Wickstrom","year":"2010","unstructured":"Wickstrom SA, Masoumi KC, Khochbin S, Fassler R, Massoumi R. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J. 2010;29:131\u201344. https:\/\/doi.org\/10.1038\/emboj.2009.317","journal-title":"EMBO J"},{"key":"6419_CR28","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/hep.27209","volume":"60","author":"RR Pannem","year":"2014","unstructured":"Pannem RR, Dorn C, Hellerbrand C, Massoumi R. Cylindromatosis gene CYLD regulates hepatocyte growth factor expression in hepatic stellate cells through interaction with histone deacetylase 7. Hepatology. 2014;60:1066\u201381. https:\/\/doi.org\/10.1002\/hep.27209","journal-title":"Hepatology"},{"key":"6419_CR29","doi-asserted-by":"publisher","unstructured":"Kim MY, Yan B, Huang S, Qiu Y. Regulating the regulators: the role of histone deacetylase 1 (HDAC1) in erythropoiesis. Int J Mol Sci. 2020:21. https:\/\/doi.org\/10.3390\/ijms21228460","DOI":"10.3390\/ijms21228460"},{"key":"6419_CR30","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.bbrc.2011.02.035","volume":"406","author":"N Mercado","year":"2011","unstructured":"Mercado N, Thimmulappa R, Thomas C, Fenwick P, Chana K, Donnelly L, et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem Biophys Res Commun. 2011;406:292\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2011.02.035","journal-title":"Biochem Biophys Res Commun"},{"key":"6419_CR31","doi-asserted-by":"publisher","first-page":"e48375","DOI":"10.15252\/embr.201948375","volume":"20","author":"A El-Naggar","year":"2019","unstructured":"El-Naggar A, Somasekharan S, Wang Y, Cheng H, Negri G, Pan M, et al. Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Rep. 2019;20:e48375. https:\/\/doi.org\/10.15252\/embr.201948375","journal-title":"EMBO Rep"},{"key":"6419_CR32","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nsmb.1899","volume":"17","author":"KM Miller","year":"2010","unstructured":"Miller KM, Tjeertes JV, Coates J, Legube G, Polo SE, Britton S, et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol. 2010;17:1144\u201351. https:\/\/doi.org\/10.1038\/nsmb.1899","journal-title":"Nat Struct Mol Biol"},{"key":"6419_CR33","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/nn.3460","volume":"16","author":"MM Dobbin","year":"2013","unstructured":"Dobbin MM, Madabhushi R, Pan L, Chen Y, Kim D, Gao J, et al. SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in neurons. Nat Neurosci. 2013;16:1008\u201315. https:\/\/doi.org\/10.1038\/nn.3460","journal-title":"Nat Neurosci"},{"key":"6419_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/ars.2014.5915","volume":"23","author":"KR Stengel","year":"2015","unstructured":"Stengel KR, Hiebert SW. Class I HDACs affect DNA replication, repair, and chromatin structure: implications for cancer therapy. Antioxid Redox Signal. 2015;23:51\u201365. https:\/\/doi.org\/10.1089\/ars.2014.5915","journal-title":"Antioxid Redox Signal"},{"key":"6419_CR35","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","volume":"18","author":"K Wong","year":"2021","unstructured":"Wong K, Hui E, Lo K, Lam W, Johnson D, Li L, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol. 2021;18:679\u201395. https:\/\/doi.org\/10.1038\/s41571-021-00524-x","journal-title":"Nat Rev Clin Oncol"},{"key":"6419_CR36","doi-asserted-by":"publisher","first-page":"7641","DOI":"10.1074\/jbc.M110.185488","volume":"286","author":"Y Qiu","year":"2011","unstructured":"Qiu Y, Stavreva D, Luo Y, Indrawan A, Chang M, Hager G. Dynamic interaction of HDAC1 with a glucocorticoid receptor-regulated gene is modulated by the activity state of the promoter. J Biol Chem. 2011;286:7641\u20137. https:\/\/doi.org\/10.1074\/jbc.M110.185488","journal-title":"J Biol Chem"},{"key":"6419_CR37","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.molcel.2006.04.019","volume":"22","author":"Y Qiu","year":"2006","unstructured":"Qiu Y, Zhao Y, Becker M, John S, Parekh B, Huang S, et al. HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription. Mol Cell. 2006;22:669\u201379. https:\/\/doi.org\/10.1016\/j.molcel.2006.04.019","journal-title":"Mol Cell"},{"key":"6419_CR38","doi-asserted-by":"publisher","first-page":"34901","DOI":"10.1074\/jbc.M109.038356","volume":"284","author":"Y Luo","year":"2009","unstructured":"Luo Y, Jian W, Stavreva D, Fu X, Hager G, Bungert J, et al. Trans-regulation of histone deacetylase activities through acetylation. J Biol Chem. 2009;284:34901\u201310. https:\/\/doi.org\/10.1074\/jbc.M109.038356","journal-title":"J Biol Chem"},{"key":"6419_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11445-0","volume":"7","author":"WB Tsai","year":"2017","unstructured":"Tsai WB, Long Y, Chang JT, Savaraj N, Feun LG, Jung M, et al. Chromatin remodeling system p300-HDAC2-Sin3A is involved in arginine starvation-induced HIF-1alpha degradation at the ASS1 promoter for ASS1 derepression. Sci Rep. 2017;7:10814. https:\/\/doi.org\/10.1038\/s41598-017-11445-0","journal-title":"Sci Rep"},{"key":"6419_CR40","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1021\/cr500452k","volume":"115","author":"BM Dancy","year":"2015","unstructured":"Dancy BM, Cole PA. Protein lysine acetylation by p300\/CBP. Chem Rev. 2015;115:2419\u201352. https:\/\/doi.org\/10.1021\/cr500452k","journal-title":"Chem Rev"},{"key":"6419_CR41","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41571-021-00579-w","volume":"19","author":"G Petroni","year":"2022","unstructured":"Petroni G, Cantley L, Santambrogio L, Formenti S, Galluzzi L. Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. Nat Rev Clin Oncol. 2022;19:114\u201331. https:\/\/doi.org\/10.1038\/s41571-021-00579-w","journal-title":"Nat Rev Clin Oncol"},{"key":"6419_CR42","doi-asserted-by":"publisher","first-page":"101084","DOI":"10.1016\/j.redox.2018.101084","volume":"25","author":"US Srinivas","year":"2019","unstructured":"Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. Redox Biol. 2019;25:101084. https:\/\/doi.org\/10.1016\/j.redox.2018.101084","journal-title":"Redox Biol"},{"key":"6419_CR43","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41568-021-00435-0","volume":"22","author":"EC Cheung","year":"2022","unstructured":"Cheung EC, Vousden KH. The role of ROS in tumour development and progression. Nat Rev Cancer. 2022;22:280\u201397. https:\/\/doi.org\/10.1038\/s41568-021-00435-0","journal-title":"Nat Rev Cancer"},{"key":"6419_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12508","volume":"7","author":"V Fernandez-Majada","year":"2016","unstructured":"Fernandez-Majada V, Welz PS, Ermolaeva MA, Schell M, Adam A, Dietlein F, et al. The tumour suppressor CYLD regulates the p53 DNA damage response. Nat Commun. 2016;7:12508. https:\/\/doi.org\/10.1038\/ncomms12508","journal-title":"Nat Commun"},{"key":"6419_CR45","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/jmcb\/mjz019","volume":"11","author":"ER Abu-Zhayia","year":"2019","unstructured":"Abu-Zhayia ER, Machour FE, Ayoub N. HDAC-dependent decrease in histone crotonylation during DNA damage. J Mol Cell Biol. 2019;11:804\u20136. https:\/\/doi.org\/10.1093\/jmcb\/mjz019","journal-title":"J Mol Cell Biol"},{"key":"6419_CR46","doi-asserted-by":"publisher","first-page":"10017","DOI":"10.1093\/nar\/gkw922","volume":"44","author":"W Roos","year":"2016","unstructured":"Roos W, Krumm A. The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair. Nucleic Acids Res. 2016;44:10017\u201330. https:\/\/doi.org\/10.1093\/nar\/gkw922","journal-title":"Nucleic Acids Res"},{"key":"6419_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16361-y","volume":"11","author":"PC Pao","year":"2020","unstructured":"Pao PC, Patnaik D, Watson LA, Gao F, Pan L, Wang J, et al. HDAC1 modulates OGG1-initiated oxidative DNA damage repair in the aging brain and Alzheimer\u2019s disease. Nat Commun. 2020;11:2484. https:\/\/doi.org\/10.1038\/s41467-020-16361-y","journal-title":"Nat Commun"},{"key":"6419_CR48","doi-asserted-by":"publisher","first-page":"9082","DOI":"10.1093\/nar\/gkaa611","volume":"48","author":"E Lebraud","year":"2020","unstructured":"Lebraud E, Pinna G, Siberchicot C, Depagne J, Busso D, Fantini D, et al. Chromatin recruitment of OGG1 requires cohesin and mediator and is essential for efficient 8-oxoG removal. Nucleic Acids Res. 2020;48:9082\u201397. https:\/\/doi.org\/10.1093\/nar\/gkaa611","journal-title":"Nucleic Acids Res"},{"key":"6419_CR49","doi-asserted-by":"publisher","first-page":"19021","DOI":"10.18632\/oncotarget.14875","volume":"8","author":"Z Ramdzan","year":"2017","unstructured":"Ramdzan Z, Ginjala V, Pinder J, Chung D, Donovan C, Kaur S, et al. The DNA repair function of CUX1 contributes to radioresistance. Oncotarget. 2017;8:19021\u201338. https:\/\/doi.org\/10.18632\/oncotarget.14875","journal-title":"Oncotarget"},{"key":"6419_CR50","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2016.05.032","volume":"380","author":"J Lu","year":"2016","unstructured":"Lu J, Tang M, Li H, Xu Z, Weng X, Li J, et al. EBV-LMP1 suppresses the DNA damage response through DNA-PK\/AMPK signaling to promote radioresistance in nasopharyngeal carcinoma. Cancer Lett. 2016;380:191\u2013200. https:\/\/doi.org\/10.1016\/j.canlet.2016.05.032","journal-title":"Cancer Lett"},{"key":"6419_CR51","doi-asserted-by":"publisher","unstructured":"Moertl S, Payer S, Kell R, Winkler K, Anastasov N, Atkinson MJ. Comparison of radiosensitization by HDAC inhibitors CUDC-101 and SAHA in pancreatic cancer cells. Int J Mol Sci. 2019:20. https:\/\/doi.org\/10.3390\/ijms20133259","DOI":"10.3390\/ijms20133259"},{"key":"6419_CR52","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejmech.2019.05.089","volume":"178","author":"Z Yang","year":"2019","unstructured":"Yang Z, Shen M, Tang M, Zhang W, Cui X, Zhang Z, et al. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy. Eur J Med Chem. 2019;178:116\u201330. https:\/\/doi.org\/10.1016\/j.ejmech.2019.05.089","journal-title":"Eur J Med Chem"},{"key":"6419_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0543-8","volume":"9","author":"S Zhang","year":"2018","unstructured":"Zhang S, Fujita Y, Matsuzaki R, Yamashita T. Class I histone deacetylase (HDAC) inhibitor CI-994 promotes functional recovery following spinal cord injury. Cell Death Dis. 2018;9:460. https:\/\/doi.org\/10.1038\/s41419-018-0543-8","journal-title":"Cell Death Dis"},{"key":"6419_CR54","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1158\/0008-5472.CAN-16-3232","volume":"77","author":"J Nicholson","year":"2017","unstructured":"Nicholson J, Jevons SJ, Groselj B, Ellermann S, Konietzny R, Kerr M, et al. E3 ligase cIAP2 mediates downregulation of MRE11 and radiosensitization in response to HDAC inhibition in bladder cancer. Cancer Res. 2017;77:3027\u201339. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-3232","journal-title":"Cancer Res"},{"key":"6419_CR55","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tips.2017.11.008","volume":"39","author":"I Vancurova","year":"2018","unstructured":"Vancurova I, Uddin M, Zou Y, Vancura A. Combination therapies targeting HDAC and IKK in solid tumors. Trends Pharmacol Sci. 2018;39:295\u2013306. https:\/\/doi.org\/10.1016\/j.tips.2017.11.008","journal-title":"Trends Pharmacol Sci"},{"key":"6419_CR56","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s13238-020-00694-x","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang X, Waschke B, Woolaver R, Chen S, Chen Z, Wang J. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. Protein Cell. 2020;11:472\u201382. https:\/\/doi.org\/10.1007\/s13238-020-00694-x","journal-title":"Protein Cell"},{"key":"6419_CR57","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.7150\/thno.21451","volume":"8","author":"Z Tan","year":"2018","unstructured":"Tan Z, Xiao L, Tang M, Bai F, Li J, Li L, et al. Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy. Theranostics. 2018;8:2329\u201347. https:\/\/doi.org\/10.7150\/thno.21451","journal-title":"Theranostics"},{"key":"6419_CR58","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1016\/j.ejca.2013.03.001","volume":"49","author":"G Li","year":"2013","unstructured":"Li G, Liu Y, Su Z, Ren S, Zhu G, Tian Y, et al. MicroRNA-324-3p regulates nasopharyngeal carcinoma radioresistance by directly targeting WNT2B. Eur J Cancer. 2013;49:2596\u2013607. https:\/\/doi.org\/10.1016\/j.ejca.2013.03.001","journal-title":"Eur J Cancer"},{"key":"6419_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29137-3","volume":"13","author":"N Jiang","year":"2022","unstructured":"Jiang N, Xie B, Xiao W, Fan M, Xu S, Duan Y, et al. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nat Commun. 2022;13:1511. https:\/\/doi.org\/10.1038\/s41467-022-29137-3","journal-title":"Nat Commun"},{"key":"6419_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41419-017-0081-9","volume":"9","author":"X Liu","year":"2018","unstructured":"Liu X, Li Y, Peng S, Yu X, Li W, Shi F, et al. Epstein-Barr virus encoded latent membrane protein 1 suppresses necroptosis through targeting RIPK1\/3 ubiquitination. Cell Death Dis. 2018;9:53. https:\/\/doi.org\/10.1038\/s41419-017-0081-9","journal-title":"Cell Death Dis"},{"key":"6419_CR61","doi-asserted-by":"publisher","first-page":"e14072","DOI":"10.15252\/emmm.202114072","volume":"13","author":"L Zhao","year":"2021","unstructured":"Zhao L, Deng X, Li Y, Hu J, Xie L, Shi F, et al. Conformational change of adenine nucleotide translocase-1 mediates cisplatin resistance induced by EBV-LMP1. EMBO Mol Med. 2021;13:e14072. https:\/\/doi.org\/10.15252\/emmm.202114072","journal-title":"EMBO Mol Med"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06419-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06419-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06419-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T02:03:51Z","timestamp":1706666631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06419-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["6419"],"URL":"https:\/\/doi.org\/10.1038\/s41419-024-06419-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"assertion":[{"value":"13 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}